v3.25.1
Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Statement [Abstract]    
Research and development expenses $ 4,581,672 $ 3,589,013
General and administrative expenses 2,435,351 1,016,741
Operating Loss (7,017,023) (4,605,754)
Other (Expense) Income:    
Grant income 252,554  
Interest expense   (255,122)
Interest income 100,098 6,642
Change in fair value of derivative liability   12,092
Total Other (Expense) Income 352,652 (236,388)
Net Loss (6,664,371) (4,842,142)
Series A Preferred cash dividend (2,089)  
Net Loss attributable to common stockholders $ (6,666,460) $ (4,842,142)
Net Loss per share, basic $ (0.15) $ (0.4)
Net Loss per share, diluted $ (0.15) $ (0.4)
Weighted-average shares outstanding, basic 43,404,947 12,173,732
Weighted-average shares outstanding, diluted 43,404,947 12,173,732

Source